|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
49,450,000 |
Market
Cap: |
1.30(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$25.5 - $46.6 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 623 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
119,323 |
119,323 |
201,796 |
291,198 |
Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,836,738 |
$12,122,941 |
Total People Sold |
1 |
1 |
15 |
17 |
Total Sell Transactions |
3 |
3 |
36 |
59 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Slonin Jonathan |
Chief Clinical Officer |
|
2022-06-06 |
4 |
S |
$61.37 |
$22,217 |
D/D |
(362) |
28,197 |
|
15% |
|
Stack David M |
CEO and Chairman |
|
2022-06-06 |
4 |
AS |
$61.37 |
$734,340 |
D/D |
(11,965) |
156,079 |
|
-15% |
|
Slonin Jonathan |
Chief Clinical Officer |
|
2022-05-23 |
4 |
OE |
$52.37 |
$104,740 |
D/D |
2,000 |
28,559 |
|
- |
|
Froimson Mark |
Director |
|
2022-05-09 |
4 |
S |
$59.37 |
$59,370 |
D/D |
(1,000) |
4,908 |
|
8% |
|
Gaugler Daryl |
Chief Operating OfficerOfficer |
|
2022-05-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,600 |
|
-20% |
|
Stack David M |
CEO and Chairman |
|
2022-04-28 |
4 |
OE |
$10.81 |
$243,225 |
D/D |
22,500 |
168,044 |
|
- |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-21 |
4 |
AS |
$73.25 |
$719,647 |
D/D |
(9,824) |
29,650 |
|
-31% |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-21 |
4 |
OE |
$42.54 |
$531,750 |
D/D |
12,500 |
39,474 |
|
- |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-20 |
4 |
AS |
$73.99 |
$722,438 |
D/D |
(9,764) |
26,974 |
|
-31% |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-20 |
4 |
OE |
$42.54 |
$531,750 |
D/D |
12,500 |
36,738 |
|
- |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-19 |
4 |
AS |
$72.25 |
$673,442 |
D/D |
(9,321) |
24,238 |
|
-26% |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-19 |
4 |
OE |
$42.54 |
$531,750 |
D/D |
12,500 |
33,559 |
|
- |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-18 |
4 |
AS |
$73.55 |
$657,611 |
D/D |
(8,941) |
21,059 |
|
-26% |
|
Reinhardt Max |
President, Rest of World |
|
2022-04-18 |
4 |
OE |
$42.54 |
$531,750 |
D/D |
12,500 |
30,000 |
|
- |
|
Molloy Anthony |
Chief Lgl & Compliance Officer |
|
2022-04-06 |
4 |
AS |
$76.03 |
$1,719,393 |
D/D |
(22,500) |
17,550 |
|
-27% |
|
Molloy Anthony |
Chief Lgl & Compliance Officer |
|
2022-04-06 |
4 |
OE |
$34.38 |
$917,408 |
D/D |
22,500 |
40,050 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2022-03-31 |
4 |
OE |
$10.81 |
$243,225 |
D/D |
22,500 |
145,544 |
|
- |
|
Dunker Kristen Marie |
Chief Administrative Officer |
|
2022-03-21 |
4 |
AS |
$72.67 |
$527,076 |
D/D |
(7,253) |
22,268 |
|
-22% |
|
Dunker Kristen Marie |
Chief Administrative Officer |
|
2022-03-21 |
4 |
OE |
$38.35 |
$309,462 |
D/D |
7,253 |
29,521 |
|
- |
|
Riker Lauren Bullaro |
Senior Vice President, Finance |
|
2022-03-10 |
4 |
S |
$71.14 |
$662,331 |
D/D |
(9,300) |
15,152 |
|
25% |
|
Riker Lauren Bullaro |
Senior Vice President, Finance |
|
2022-03-10 |
4 |
OE |
$10.81 |
$100,533 |
D/D |
9,300 |
24,452 |
|
- |
|
Pace Gary W |
Director |
|
2022-03-03 |
4 |
OE |
$10.81 |
$75,670 |
D/D |
7,000 |
136,530 |
|
- |
|
Longenecker John P Phd |
Director |
|
2022-03-03 |
4 |
S |
$71.74 |
$502,145 |
D/D |
(7,000) |
18,823 |
|
25% |
|
Longenecker John P Phd |
Director |
|
2022-03-03 |
4 |
OE |
$10.81 |
$75,670 |
D/D |
7,000 |
25,823 |
|
- |
|
Pace Gary W |
Director |
|
2022-03-01 |
4 |
S |
$67.75 |
$92,072 |
D/D |
(1,359) |
129,530 |
|
16% |
|
781 Records found
|
|
Page 5 of 32 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|